Boshoff currently serves as chief oncology officer and is credited with delivering 24 approved new medicines and biosimilars during his 11-year tenure at the company. Boshoff has also worked as Pfizer’s head of development in Japan and as chief development officer for oncology and rare disease.
“Dr. Boshoff is the ideal leader to propel Pfizer’s R&D engine forward and transform it into a world-leading organization with a more focused strategy,” Pfizer CEO Albert Bourla said in the company’s statement. He credited Boshoff with running one of the company’s most productive divisions and said he has a “compelling vision” for future research and development.
As the new head of research, Boshoff will be tasked with revving up a pipeline that some investors have found disappointing. Pfizer achieved an astonishing success developing a COVID-19 vaccine in a matter of months in 2020 and raked in billions of dollars during the pandemic, pushing its shares above $59 in late 2021. Since then, the stock has more than halved, however.
The activist investor Starboard Value argues that Pfizer executives wasted their COVID-19 windfall on bad acquisitions while neglecting innovation. Last month, Starboard pushed the company’s board “to hold management accountable for earning appropriate returns on R&D and M&A moving forward.” READ MORE
By Kristin Jensen
Source: biopharmadive.com
The last few days have been a rollercoaster for the pharmaceutical industry. Mexico and Canada were bracing themselves for the effects of double-digit tariffs from the US, only for President Donald Trump to pause the levies after striking a deal with the two countries.
BD (Becton, Dickinson and Company), a leading global medical technology company, announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation.
Jabil, a global provider of engineering, manufacturing, and supply chain solutions, has acquired Pharmaceutics International (Pii), a US contract development and manufacturing organization (CDMO) specializing in early-stage, clinical, and commercial volume aseptic filling, lyophilization, and oral solid dose manufacturing.